This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2026 Remove Capital Structure Remove Equity Related Topics
Dividends Marketability Technology More Related Topics >
article thumbnail

SomaLogic Issues Letter to Stockholders Reiterating Recommendation for Value Maximizing Merger with Standard BioTools

Benzinga

DECEMBER 21, 2023

We expect this will deliver $300 million in combined revenue by 2026. Accelerates our path to profitability through enhanced operating leverage and an anticipated $80 million in run-rate cost synergies by 2026. The capital structure of the combined company is not risky.

Capital Structure 40
Capital Structure Dividends Equity Marketability 40
article thumbnail

Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools

Benzinga

OCTOBER 4, 2023

The combined company, with a pro-forma equity value of over $1 billion based on Standard BioTools' closing share price on October 3, 2023, will be a leading provider of differentiated multi-omics tools for research. The transaction is expected to generate $80 million in annual cost synergies by 2026. and BOULDER, Colo.,

Technology 40
Technology Capital Structure Equity Marketability 40
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024